CBPO Holdings Limited completed its acquisition of China Biologic Products Holdings for $4.76 billion, or $120 per share. China Biologic Products became a private company and its shares are no longer traded on NASDAQ.

China Biologic Products Holdings' GAAP net income for 2020 was $178,321 million, up 9.1% from $163,395 million in the previous year. Revenues increased 4.1% to $524,368 million from $503,745 million a year earlier.

China Biological's shareholders have approved the merger with CBPO Group Limited. They will receive $120 for each share of their company. After the merger is completed, China Biological will become a private company and its shares will no longer be traded on NASDAQ.

China Biologic Products Holdings' net profit under GAAP for 9 months of 2020 was $149.216 million, up 1.6% from $146.798 million the previous year. Revenue increased 2.7% to $412.239 million, against $401.587 million a year earlier.